ACADIA PHARMACEUTICALS INC

ACAD - CIK 0001070494

Market cap$3.65 B

Rank#1647

SEC filings1,357

ACADIA PHARMACEUTICALS INC trades as ACAD and has a market capitalization of $3.65 B, making it the #1647 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.07B, up 11.9% from the prior year and net income of $391.00M. This page tracks ACADIA PHARMACEUTICALS INC through 1,357 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$1.07BFY 2025

Net income (latest FY)$391.00MFY 2025

Operating cash flow (latest FY)$109.84MFY 2025

Total assets (latest FY)$1.56BFY 2025

Net margin36.5%latest FY

Financial performance

Over the last 9 fiscal years ACADIA PHARMACEUTICALS INC's revenue grew from $17.33M to $1.07B, a compound annual growth rate of 58.1%. Net profit margin expanded from -1565.9% to 36.5% over the same period - every figure below comes from the company's audited annual filings.

ACAD annual revenueView details

Key statistics

Market cap: $3.65 B
Share price (derived)market cap / shares outstanding: $21.34
P/E ratio (trailing FY): 9.3
EPS (diluted)FY 2025: $2.30
Shares outstandingas of 2026-04-29: 0.17B
Total equityas of 2026-03-31: $1.25B
Return on equity: 31.3%
Cash & equivalentsas of 2026-03-31: $282.21M

Latest filings

Filing	Type	Filed
Insider sale notice	144	2026-05-26
Quarterly report	10-Q	2026-05-07
Major company event	8-K	2026-05-06
Insider trade	4	2026-05-05
Insider trade	4	2026-05-05
Major company event	8-K	2026-05-01
SCHEDULE 13G	-	2026-04-28
Annual report to shareholders	ARS	2026-04-24

Browse the full filing history (1,357 filings)

Recent press releases

Acadia Pharmaceuticals - Acadia Pharmaceuticals Reports Fourth ...
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview · Total revenues of $1.22 to $1.28 billion. · NUPLAZID ...
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 ...
For the fourth quarter of 2024, Acadia reported net income of $143.7 million, or $0.86 per common share, compared to a net income of $45.8 ...
Acadia Pharmaceuticals Reports First Quarter 2025 Financial ...
First quarter total revenues of $244.3 million, up 19% year-over-year. - First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, ...

Similar companies

The largest companies sharing ACADIA PHARMACEUTICALS INC's SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T ACAD vs LLY

JNJJohnson & Johnson$573.98 B ACAD vs JNJ

ABBVAbbVie Inc.$399.47 B ACAD vs ABBV

MRKMerck & Co., Inc.$293.16 B ACAD vs MRK

AZNAstraZeneca PLC$286.27 B ACAD vs AZN

Frequently asked questions

What is ACADIA PHARMACEUTICALS INC's market cap?

ACADIA PHARMACEUTICALS INC (ACAD) has a market capitalization of $3.65 B as of 2026-06-10, ranking #1647 among US-listed companies.

How much revenue does ACADIA PHARMACEUTICALS INC make?

ACADIA PHARMACEUTICALS INC reported revenue of $1.07B for fiscal year 2025, an increase of 11.9% year over year.

Is ACADIA PHARMACEUTICALS INC profitable?

Yes. ACADIA PHARMACEUTICALS INC reported net income of $391.00M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.